ABB introduces Battery Energy Storage Systems-as-a-Service to simplify renewable energy adoption
ZURICH, SWITZERLAND, May 21, 2025 (GLOBE NEWSWIRE) --
ABB today announced the launch of its new Battery Energy Storage Systems-as-a-Service (BESS-as-a-Service) – a flexible, zero-CapEx solution designed to accelerate the shift to clean, resilient and affordable energy. BESS-as-a-Service is the first in a range of next generation service models being developed by ABB to remove the barriers to clean technology adoption and accelerate industries' transition to net zero.
With demand for energy storage expected to surge, ABB's BESS-as-a-Service offers companies a turnkey path to energy independence and sustainability. The International Energy Agency (IEA) projects a sixfold increase in global storage capacity by 20301, with commercial and industrial systems alone expected to surge nearly tenfold to 560 GWh – underscoring the critical role of battery energy storage in enabling cleaner, more resilient power systems2.
Requiring no upfront capital investment, BESS-as-a-Service enables companies spanning a wide range of industries – from data centers to transport and logistics to commercial buildings – to benefit from advanced energy storage through a quarterly service fee.
The offer includes all hardware, software and lifecycle support, with ABB managing deployment, maintenance and optimization so businesses can focus on their core operations while improving energy efficiency, resilience and long-term sustainability. Designed to be technology-agnostic, BESS-as-a-Service works with any type of battery technology, giving customers the flexibility to take advantage of the latest innovations without being tied to a single system.
BESS-as-a-Service is underpinned by performance guarantees, as well as coverage for maintenance costs and energy trading brokerage fees. By managing all aspects of energy market participation, ABB enables customers to effortlessly reap immediate financial benefits from selling excess energy.
Stuart Thompson, Division President, at ABB's Electrification Service Division, said: 'In today's volatile energy market, businesses need reliability and cost predictability above all else. Customers tell us that while they want to deploy the latest technologies to improve energy security and reduce their emissions and costs, they face financial obstacles. By shifting from capital expenditure to a more predictable operational expenditure approach, ABB's BESS-as-a-Service enables businesses to immediately strengthen their energy security, slash peak demand charges, and generate new revenue streams. We see BESS-as-a-Service as not just a new offering but a strategic lever for the Division's growth and innovation. We see significant potential to scale this globally, especially as more industries seek flexible, low-risk pathways to decarbonization.'
ABB is currently conducting feasibility assessments with prospective customers to ensure immediate financial benefits before the deployment of BESS-as-a-Service. This evaluation is a prerequisite for installation, ensuring that customers can achieve net financial advances from day one. Feasibility studies to date have centred on the following segments:
'With BESS-as-a-Service, we are redefining the economics of clean energy adoption – delivering the flexibility and financial returns businesses need to decarbonize with confidence. It allows businesses to adopt advanced energy solutions without the financial strain of large capital investment and empowers them to take control of their energy needs, strengthen their resilience and unlock new value from their assets,' Thompson said.
To learn more about BESS-as-a-Service, visit https://bess-as-a-service.abb.com/
ABB Electrification is a global technology leader enabling the efficient and reliable distribution of electricity from source to socket. With more than 50,000 employees across 100 countries, we collaborate with our customers and partners to solve the world's greatest challenges in electrical distribution and energy management. As the energy transition accelerates and electricity demands grow, we are electrifying the world in a safe, smart and sustainable way. At ABB, we are 'Engineered to Outrun', and we are passionate about helping our customers and partners do the same. go.abb/electrification
1 Batteries and Secure Energy Transition, World Energy Outlook Special Report, International Energy Agency, 2024
2Global Energy Storage Market Outlook Update: Q1 2025, Wood Mackenzie
Attachments
Media Relations ABB +41 43 317 71 11 [email protected] Investor Relations ABB +41 43 317 71 11 [email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
36 minutes ago
- Bloomberg
Tom Cruise's Final ‘Mission Impossible' Tops China Box Office
Mission: Impossible – The Final Reckoning posted the biggest opening for a US film in the country this year, defying trade and geopolitical tensions between Washington and Beijing. Paramount Global 's eighth installment in the action franchise earned $25.2 million across 11,847 locations in China during the opening weekend, the studio said in a statement. The film is likely to become the top-performing US release in the country for 2025, with Warner Bros Entertainment Inc. 's A Minecraft Movie so far holding the lead with about $29 million since its April 4 debut, according to ticketing platform Maoyan.
Business Upturn
an hour ago
- Business Upturn
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
By GlobeNewswire Published on June 2, 2025, 10:15 IST Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus hormone therapy versus hormone therapy alone, with positive trend in overall survival (OS) 1 Pluvicto is already approved for metastatic castration-resistant prostate cancer (mCRPC) and now shows potential in patients in an earlier disease setting 1,2 Novartis to present results at an upcoming medical meeting and, based on FDA feedback, will submit for regulatory review in the second half of the year Novartis is investigating a broad portfolio of RLTs in advanced cancers, including breast, colon, lung and pancreatic and is investing in multiple manufacturing facilities, with industry-leading infrastructure to accelerate delivery of RLTs to patients Basel, June 2, 2025 – Novartis today announced topline results from a pre-specified interim analysis of the Phase III PSMAddition trial. The trial met its primary endpoint with a statistically significant and clinically meaningful benefit in radiographic progression-free survival (rPFS) with a positive trend in overall survival (OS) in patients with prostate-specific membrane antigen (PSMA)-positive metastatic hormone-sensitive prostate cancer (mHSPC) treated with radioligand therapy (RLT), Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan), in combination with standard of care (SoC) versus SoC alone1. In PSMAddition, the SoC is a combination of androgen receptor pathway inhibitor (ARPI) therapy and androgen deprivation therapy (ADT)3. Almost all mHSPC patients ultimately progress to metastatic castration-resistant prostate cancer (mCRPC)4. There is a need for additional treatment options with novel mechanisms of action that further delay progression, prolong OS and improve disease control compared to the current SoC, while showing a favorable safety and tolerability profile. 'The progression from metastatic hormone-sensitive prostate cancer to castration-resistant disease remains a formidable challenge that can profoundly impact the survival of patients,' said Shreeram Aradhye, M.D., President, Development and Chief Medical Officer at Novartis. 'These results further strengthen our confidence in Pluvicto as a PSMA-targeted radioligand therapy. Following the recent FDA approval based on the PSMAfore trial in metastatic castration-resistant prostate cancer, these data suggest using it in an earlier disease setting could advance care and address a significant unmet need for hormone-sensitive prostate cancer patients.' This is the third positive read-out for Pluvicto in a Phase III trial, following the VISION and PSMAfore studies5,6. Results from PSMAddition in mHSPC show potential for treatment in an earlier setting with Pluvicto, which was recently granted US Food and Drug Administration (FDA) approval for earlier use in mCRPC, based on results from PSMAfore1,2. Novartis is harnessing the innovation of world-class scientists, strategic partnerships and one of the industry's most competitive pipelines to explore the potential of new, targeted therapies and precision medicine platforms to address the greatest unmet needs in prostate cancer. Data will be presented at an upcoming medical meeting and, based on FDA feedback, will be submitted for regulatory review in the second half of the year. About PSMAddition study PSMAddition (NCT04720157) is a Phase III, open-label, prospective, 1:1 randomized study comparing the efficacy and safety of Pluvicto in combination with SoC (ARPI + ADT) vs. SoC alone in adult patients with PSMA-positive mHSPC3. Patients randomized to the SoC alone arm are allowed to crossover to receive Pluvicto, upon confirmation of radiographic progression by blinded independent review committee (BIRC) and per the discretion of the treating physician3. The primary endpoint is rPFS, defined as the time to radiographic progression by PCWG3-modified RECIST V1.1 (as assessed by BIRC) or death3. The key secondary endpoint of OS is defined as time to death due to any cause3. About Pluvicto™ (INN: lutetium (177Lu) vipivotide tetraxetan) Pluvicto is an intravenous RLT that combines a targeting compound (a ligand) with a therapeutic radionuclide (a radioactive particle, in this case lutetium-177)5,7. After administration into the bloodstream, Pluvicto binds to PSMA-expressing target cells, including prostate cancer cells that express PSMA, a transmembrane protein5,7. Once bound, energy emissions from the radioisotope damage the target cells and nearby cells, disrupting their ability to replicate and/or triggering cell death7. Pluvicto is the only PSMA-targeted agent approved for PSMA-positive mCRPC and is the first targeted RLT to demonstrate a clinical benefit for patients with PSMA-positive mHSPC1. Novartis is investigating Pluvicto in earlier stages of disease, including oligometastatic prostate cancer (PSMA-DC, NCT05939414). Novartis and radioligand therapy (RLT) Novartis is reimagining cancer care with RLT for patients with advanced cancers. By harnessing the power of targeted radiation and applying it to advanced cancers, RLT is designed to deliver treatment directly to target cells, anywhere in the body8,9. Novartis is investigating a broad portfolio of RLTs, exploring new isotopes, ligands and combination therapies to look beyond gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and prostate cancer and into breast, colon, lung and pancreatic cancer. Novartis has established global expertise, with specialized supply chain and manufacturing capabilities across its network of RLT production sites. To support growing demand for RLTs, we have expanded production capabilities in Millburn (NJ), Zaragoza (Spain), Ivrea (Italy) and a state-of-the-art facility in Indianapolis (IN). In Carlsbad (CA), Novartis is establishing its third US-based RLT manufacturing site to support expanded use of RLTs, create resiliency in its manufacturing network and optimize the delivery of medicines to patients on the West Coast. Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as 'potential,' 'can,' 'will,' 'may,' 'could,' 'trend,' 'potentially,' 'upcoming,' 'progression,' 'progress,' 'investigating,' 'investing,' 'look beyond,' or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for Pluvicto, or regarding potential future revenues from Pluvicto. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Pluvicto will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that Pluvicto will be commercially successful in the future. In particular, our expectations regarding Pluvicto could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide. Reimagine medicine with us: Visit us at and connect with us on LinkedIn, Facebook, X/Twitter and Instagram. References Data on file. Pluvicto [prescribing information]. Millburn, NJ: Advanced Accelerator Applications USA, Inc.; 2025. An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC (PSMAddition). identifier: NCT04720157. Updated March 5, 2025. Accessed June 2, 2025. Oing C, Bristow RG. Systemic treatment of metastatic hormone-sensitive prostate cancer—upfront triplet versus doublet combination therapy. ESMO Open 2023l doi: 10.1016/ Sartor O, J. de Bono KN, Chi K, et al. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. NEJM 2021; doi: 10.1056/NEJMoa2107322. Morris M, Castellano D, Herrmann K, et al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. The Lancet 2024; doi: 10.1016/S0140-6736(24)01653-2. University of Chicago Medicine. Lutetium-177 PSMA Therapy for Prostate Cancer (Pluvicto). Accessed June 18, 2024. Jadvar H. Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment [published correction appears in AJR Am J Roentgenol. 2017 Oct;209(4):949. doi: 10.2214/AJR.17.18875]. AJR Am J Roentgenol. 2017;209(2):277-288. doi:10.2214/AJR.17.18264 Jurcic JG, Wong JYC, Knoc SJ, et al. Targeted radionuclide therapy. In: Tepper JE, Foote RE, Michalski JM, eds. Gunderson & Tepper's Clinical Radiation Oncology. 5th ed. Elsevier, Inc. 2021;71(3):209-249 # # # Novartis Media Relations E-mail: [email protected] Novartis Investor RelationsCentral investor relations line: +41 61 324 7944 E-mail: [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Yahoo
4 hours ago
- Yahoo
Mistakes To Avoid When Installing An EV Charging Station In Your Garage
Electric vehicle sales have experienced years of robust growth, and this trend is expected to continue. According to the International Energy Agency, electric vehicle sales increased by more than 40% in 2023 compared to 2022 in the United States. And if you're an electric vehicle owner, a home EV charging station is essential. Now, although charging your vehicle at home offers several benefits, there are some mistakes you must avoid when you install a home EV charging station in your garage. The mistakes include amateur installations, forgetting to access your home's electrical system, and buying the wrong type of charger. While the cost of installing an EV charger in your home can be a bit pricey, that amount will likely increase if you have any of these issues. Ensuring that you avoid them will allow you to enjoy the benefits of your home charging station. For many electric vehicle owners, the convenience of having a charging station at home for their electric vehicle is a major advantage. The ability to charge the car while cooking dinner and relaxing in the evening saves time and money. In addition, it is better for your car's battery. The fast chargers found in public charging stations can degrade your battery and shorten its life when used too frequently. A home EV charger allows you to minimize the use of these public charging stations. Read more: The Best Ways To Heat Your Garage Without An Electric Space Heater Choosing the wrong type of EV charging station for your vehicle and your charging needs is a common mistake. The most frequently used home EV chargers are Level 1 and Level 2 charging stations. The Level 1 charger usually comes with your vehicle and plugs into a typical 110V outlet. However, these chargers are extremely slow, taking as long as 24 hours to fully charge the vehicle. Level 2 chargers are faster but require a dedicated 220V circuit. Neglecting to evaluate your home electrical system is another common mistake people make when installing an EV charger. Before buying an electric car, update your garage and home to ensure your electrical infrastructure has the capacity needed to handle the power demand of an EV charger. Older homes were designed when homes had less demand for electricity, so an upgrade may be needed. A potentially dangerous mistake is not hiring a professional for your EV charging station installation. This is particularly true when you need an electrical service upgrade. A licensed electrician has the training and knowledge of electrical systems, EV charger installation, and local building and electrical codes to handle all aspects of the job, from evaluating the electrical infrastructure to installing the EV charger. The best way to avoid mistakes when you install an EV charging station in the garage is to work with an experienced, trained professional electrician. A licensed contractor certified in electric vehicle infrastructure installation will ensure that your charging station is properly installed and in compliance with all current electrical codes and regulations. Another way you can avoid costly mistakes when installing an EV charging station is to think ahead and plan for the future. Buying a charger that works with a specific vehicle brand may not meet your long-term needs. Selecting a charger with universal compatibility ensures that it will work with any other type of electric vehicle you may buy in the future. Taking the time to research your options and having your electrical system evaluated by a professional will also help you get informed on the total cost of EV charger installation. When you consider how much it costs to charge an electric car at a public charging station, you will find that installing an EV charger at home is worth the investment in the long run. Enjoyed this article? Get expert home tips, DIY guides, and design inspiration by signing up to the House Digest newsletter! Read the original article on House Digest.
